Home > News > Nexttobe extends loan to Oasmia
December 2nd, 2013
Nexttobe extends loan to Oasmia
Abstract:
Oasmia Pharmaceutical AB develops new generations
of drugs in the field of human and veterinary oncology. The company's product
development aims to create and manufacture novel nanoparticle formulations and
drug-delivery systems based on well-established cytostatics which, in
comparison with current alternatives, show improved properties, reduced
side-effects, and expanded applications. The company's product development is
based on its proprietary in-house research and company patents. Oasmia is
listed on NASDAQ OMX Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX,
ISIN SE0000722365).
Source:
wsj.com
Related News Press |
News and information
Simulating magnetization in a Heisenberg quantum spin chain April 5th, 2024
NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
VC/Funding/Angel financing/Loans/Leases/Crowdfunding
Graphene Flagship start-up Bedimensional closes a second €10 million investment round February 10th, 2023
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Nanomedicine
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||